Abstract
Background: Coronavirus disease 2019 (COVID-19) patients who need intensive medical care often require oxygen ventilation, but the number of ventilation machines is limited, and in some parts of the world, they are not available at all. In addition to patients for whom there is no access to ventilation machines there is also a considerable population of patients for whom ventilation is not sufficient for them to survive a critical state. Methods: Here, we propose and test an alternative oxygen supply through accelerated transdermal oxygen delivery. Covering the entire body with liquid fluorocarbons, which can dissolve 20 times more oxygen than water, we hypothesized to increase the contribution of transcutaneous respiration by a sustained amount. Results: Experiments applying pure medical grade perfluorodecalin on nude mice did not change their oxygenation in the blood under induced hypoxic conditions compared to control mice. However, increases in blood oxygenation below 2% could not be detected with the applied method. Conclusions: We could not establish a proof-of-principle for a substantial increase in oxygen supply by transdermal oxygen delivery in mammals.
Highlights
The major cause of death in coronavirus disease 2019 (COVID-19) patients is severe atypical pneumonia and respiratory distress (Hui et al, 2020)
Here, we propose and test an alternative oxygen supply through accelerated transdermal oxygen delivery
Experiments applying pure medical grade perfluorodecalin on nude mice did not change their oxygenation in the blood under induced hypoxic conditions compared to control mice
Summary
The major cause of death in coronavirus disease 2019 (COVID-19) patients is severe atypical pneumonia and respiratory distress (Hui et al, 2020). Severe acute respiratory distress syndrome in these patients is treated mainly with mechanical ventilation, which supports O2 delivery through the lungs, and with anti-inflammatory and anti-viral medication or even targeting the receptor used by the virus to invade the lungs and the epithelium, angiotensin-converting enzyme 2 (Zhang et al, 2020). The increasing number of patients and the finite number of healthy and operationally trained medical care personnel and machines limits the choice of therapeutic strategies that are available for all that require assistance. Coronavirus disease 2019 (COVID-19) patients who need intensive medical care often require oxygen ventilation, but the number of ventilation machines is limited, and in some parts of the world, they are not available at all. Conclusions: We could not establish a proof-of-principle for a substantial increase in oxygen supply by transdermal oxygen delivery in mammals
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
